FBXO9: A Potential Drug Target and Biomarker (G26268)

Target Name: FBXO9

NCBI ID: G26268

FBXO9

FBXO9: A Potential Drug Target and Biomarker

FacebookeXpress (FBXO9) is a protein that is found in all living cells of the human body. It is a small transmembrane protein that is composed of 90 amino acids. FBXO9 is categorized as a long non-coding RNA (lncRNA) and has been shown to play a role in various cellular processes.

One of the interesting aspects of FBXO9 is its potential as a drug target. FBXO9 has been shown to interact with various signaling pathways, including the TGF-β pathway. This pathway is involved in cell growth, differentiation, and repair, and is a key regulator of many diseases, including cancer.

FBXO9 has also been shown to interact with the NF-kappa-B pathway, a signaling pathway that is involved in inflammation and pain. This pathway is also involved in the development of many diseases, including heart disease and neurodegenerative disorders.

In addition to its potential as a drug target, FBXO9 has also been shown to have potential as a biomarker. FBXO9 has been shown to be expressed in various tissues and fluids, including blood, urine, and tissue samples from cancer patients. This suggests that it may be a useful biomarker for the diagnosis and treatment of cancer.

FBXO9 has also been shown to play a role in the regulation of cellular processes that are important for human health. For example, it has been shown to regulate the production of platelets, which are important for blood clotting. FBXO9 has also been shown to regulate the production of white blood cells, which are important for immune function.

In conclusion, FBXO9 is a protein that has shown potential as a drug target and biomarker. Further research is needed to fully understand its role in cellular processes and its potential as a therapeutic agent.

Protein Name: F-box Protein 9

Functions: Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins and plays a role in several biological processes such as cell cycle, cell proliferation, or maintenance of chromosome stability (PubMed:34480022, PubMed:23263282). Ubiquitinates mTORC1-bound TTI1 and TELO2 when they are phosphorylated by CK2 following growth factor deprivation, leading to their degradation. In contrast, does not mediate ubiquitination of TTI1 and TELO2 when they are part of the mTORC2 complex. As a consequence, mTORC1 is inactivated to restrain cell growth and protein translation, while mTORC2 is the activated due to the relief of feedback inhibition by mTORC1 (PubMed:23263282). Plays a role in maintaining epithelial cell survival by regulating the turn-over of chromatin modulator PRMT4 through ubiquitination and degradation by the proteasomal pathway (PubMed:34480022). Regulates also PPARgamma stability by facilitating PPARgamma/PPARG ubiquitination and thereby plays a role in adipocyte differentiation (By similarity)

The "FBXO9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FBXO9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets